Ocrelizumab

Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
COVID-19 vaccination in patients with MS 7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani • 13 Oct 2021
Delaying MS treatment to boost COVID-19 vaccination effects 4:37
Delaying MS treatment to boost COVID-19 vaccination effects
Anat Achiron • 12 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
How does ublituximab compare to other anti-CD20 mAbs? 1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman • 15 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
The future of biomarkers in MS: novel discoveries and defining protocols 2:12
The future of biomarkers in MS: novel discoveries and defining protocols
Charlotte Teunissen • 6 Oct 2021
Fingolimod and ocrelizumab prevent successful immune responses to COVID-19 vaccination in MS 5:26
Fingolimod and ocrelizumab prevent successful immune responses to COVID-19 vaccination in MS
Anat Achiron • 12 Oct 2021
Neuroregenerative agents in progressive multiple sclerosis 1:08
Neuroregenerative agents in progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Current treatments for primary and secondary progressive multiple sclerosis 4:46
Current treatments for primary and secondary progressive multiple sclerosis
Xavier Montalban • 23 Sep 2021
Work productivity improves in patients with RRMS treated with ocrelizumab 4:56
Work productivity improves in patients with RRMS treated with ocrelizumab
Giancarlo Comi • 21 Jun 2021
Why are B-cells such a valuable target in MS? 3:09
Why are B-cells such a valuable target in MS?
Giancarlo Comi • 21 Jun 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Next steps in MS treatment: optimizing what we have 3:36
Next steps in MS treatment: optimizing what we have
Giancarlo Comi • 21 Jun 2021
CASTING: ocrelizumab safety profile in RRMS 2:16
CASTING: ocrelizumab safety profile in RRMS
Celia Oreja-Guevara • 20 Jun 2021
NfL to monitor treatment effects in MS 3:26
NfL to monitor treatment effects in MS
Charlotte Teunissen • 4 Jun 2021
The content of VJNeurology is intended for healthcare professionals